Francis Financial Inc. Acquires New Stake in Eli Lilly and Company (NYSE:LLY)

Francis Financial Inc. acquired a new stake in shares of Eli Lilly and Company (NYSE:LLY) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 375 shares of the company’s stock, valued at approximately $219,000.

Several other large investors also recently added to or reduced their stakes in the business. Elwood & Goetz Wealth Advisory Group LLC raised its position in Eli Lilly and Company by 7.2% during the fourth quarter. Elwood & Goetz Wealth Advisory Group LLC now owns 534 shares of the company’s stock valued at $311,000 after purchasing an additional 36 shares in the last quarter. Ballast Inc. increased its holdings in Eli Lilly and Company by 12.1% during the 4th quarter. Ballast Inc. now owns 4,636 shares of the company’s stock valued at $2,702,000 after purchasing an additional 501 shares during the period. Evanson Asset Management LLC increased its holdings in Eli Lilly and Company by 4.6% during the 4th quarter. Evanson Asset Management LLC now owns 1,279 shares of the company’s stock valued at $746,000 after purchasing an additional 56 shares during the period. Accel Wealth Management increased its holdings in Eli Lilly and Company by 7.3% during the 4th quarter. Accel Wealth Management now owns 884 shares of the company’s stock valued at $515,000 after purchasing an additional 60 shares during the period. Finally, Trueblood Wealth Management LLC purchased a new position in Eli Lilly and Company during the 4th quarter valued at about $463,000. Institutional investors own 82.53% of the company’s stock.

Analyst Ratings Changes

Several analysts have weighed in on LLY shares. TheStreet raised Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Truist Financial reaffirmed a “buy” rating and set a $850.00 price objective on shares of Eli Lilly and Company in a research report on Friday, March 22nd. Wells Fargo & Company boosted their price target on Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. Cantor Fitzgerald reissued an “overweight” rating and issued a $815.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, February 20th. Finally, Morgan Stanley boosted their price target on Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a research report on Friday, February 16th. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and an average price target of $689.52.

Eli Lilly and Company Trading Down 0.0 %

Shares of Eli Lilly and Company stock opened at $777.96 on Friday. Eli Lilly and Company has a fifty-two week low of $334.58 and a fifty-two week high of $800.78. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. The firm has a 50-day simple moving average of $730.97 and a two-hundred day simple moving average of $637.01. The company has a market cap of $739.19 billion, a P/E ratio of 134.13, a price-to-earnings-growth ratio of 1.71 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The firm had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. During the same quarter in the prior year, the firm earned $2.09 EPS. The company’s revenue for the quarter was up 28.1% on a year-over-year basis. As a group, equities analysts predict that Eli Lilly and Company will post 12.42 earnings per share for the current fiscal year.

Insider Activity at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 1,180 shares of the firm’s stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $645.60, for a total value of $761,808.00. Following the sale, the insider now directly owns 99,542,630 shares in the company, valued at approximately $64,264,721,928. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In the last quarter, insiders sold 195,055 shares of company stock valued at $125,254,657. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.